Usana Health Sciences INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
Peter Benedict, CHIEF INFORMATION OFFICER of Usana Health Sciences Inc, reported multiple transactions in common stock on July 25, 2026.
NYSE
Kathryn Michelle Armstrong, CHIEF SCIENTIFIC OFFICER of Usana Health Sciences Inc, reported multiple transactions in common stock on July 25, 2026.
NYSE
Timothy E Wood, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.
NYSE
Frederic J Winssinger, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.
NYSE
J Scott Nixon, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.
NYSE
Gilbert A Fuller, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.
NYSE
Peggie Pelosi, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.
NYSE
John Turman Fleming, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.
NYSE
Xia Ding, a Director of Usana Health Sciences Inc, reported multiple transactions in common stock on July 23, 2026.
NYSE
USANA Health Sciences reports a transaction where Chief Commercial Officer Brent Neidig sold 5,002 shares of common stock.
NYSE
USANA Health Sciences Chief Commercial Officer, Brent Neidig, reported the sale of company stock on June 12th and June 15th, 2026.
NYSE
Paul A. Jones, Chief People Officer of USANA Health Sciences, Inc., sold 5,561 shares of common stock on June 8, 2026.
NYSE
USANA Health Sciences Director John Turman Fleming acquired 2,450 shares of common stock on June 1, 2026, for $17.93 per share.
NYSE
USANA Health Sciences Chief People Officer Paul A. Jones sold 6,813 shares of common stock on May 28, 2026.
NYSE
USANA Health Sciences CFO Doug Iekking sold 5,360 shares of common stock at an average price of $18.7525 per share.
NYSE
USANA Health Sciences Director Gilbert A. Fuller reported a transaction involving 1,057 shares of common stock on May 22, 2026.
NYSE
USANA Health Sciences reports a Form 4 filing detailing Director Timothy E. Wood's acquisition of 6,527 restricted stock units.
NYSE
Director J. Scott Nixon of USANA Health Sciences reported the acquisition of 6,527 restricted stock units.
NYSE
USANA Health Sciences Director Peggie Pelosi acquired 6,527 restricted stock units on May 7, 2026, as disclosed in a Form 4 filing.
NYSE
USANA Health Sciences Director John Turman Fleming acquired 6,527 restricted stock units on May 7, 2026, as disclosed in a Form 4 filing.
NYSE
USANA Health Sciences Director Frederic J. Winssinger acquired 6,527 restricted stock units on May 7, 2026, as detailed in a Form 4 filing.
NYSE
USANA Health Sciences Director Gilbert A. Fuller acquired 6,527 restricted stock units, representing a contingent right to receive common stock.
NYSE
Director Ding Xia acquired 6,527 restricted stock units of USANA Health Sciences Inc. on May 7, 2026.
NYSE
USANA Health Sciences Chief Legal Officer Joshua Foukas sold 3,791 shares of common stock on May 7, 2026.
NYSE
USANA Health Sciences Director Timothy E. Wood reported transactions involving common stock and restricted stock units.
NYSE
Frederic J. Winssinger, a Director at USANA Health Sciences Inc., acquired 1,057 shares of common stock through restricted stock units.
NYSE
USANA Health Sciences Director Scott Nixon acquired 1,057 restricted stock units, increasing his beneficial ownership.
NYSE
USANA Health Sciences Director Gilbert A. Fuller acquired 1,057 shares of common stock through restricted stock units on April 23, 2026.
NYSE
Peggie Pelosi, a Director at USANA Health Sciences Inc., has reported transactions involving restricted stock units and common stock.
NYSE
USANA Health Sciences Director John Turman Fleming acquired 1,057 restricted stock units on April 23, 2026, increasing his beneficial ownership.